Document Detail

Evaluation of red blood cell deformability and uterine blood flow in pregnant women with preeclampsia or iugr and reduced uterine blood flow following the intravenous application of magnesium.
MedLine Citation:
PMID:  15617633     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Red blood cells (RBC) deformability is one of the factors determining microcirculation. In preeclampsia (PE) and some cases of intrauterine growth restriction (IUGR), RBC deformability and, consequently, microcirculation appear to be impaired. Magnesium sulfate is administered to reduce the risk of seizures in PE. The aim of our study was to detect the effect of 24-hour intravenous (IV) magnesium on RBC deformability and on uterine artery blood flow in pregnant patients with preeclampsia or IUGR and pathologic uterine blood flow.
METHODS: Magnesium IV (1 g/h) was administered to 25 pregnant women with reduced uterine blood flow for a period of at least 24 hours. The RBC deformability was measured by uterine artery Doppler. Measurements were taken before the start of magnesium therapy and 24 h later. Magnesium plasma levels were measured at the same time.
RESULTS: High plasma levels of magnesium improve RBC deformability from E = 0.109 (SD +/- 0.023) to E = 0.115 (SD +/- 0.021) after 24 h IV magnesium (p = 0.043). There is no correlation of E to the plasma magnesium level either before or after 24 h magnesium treatment. Blood volume flow in the uterine arteries increased significantly from 5.09 mL/s (SD +/- 3.03) to 10.02 mL/s (SD +/- 5.86) after 24 h magnesium (p = 0.0002). The differences in the resistance index do not significantly differ from 0 (p = 0.46).
CONCLUSION: A high IV dosage of magnesium over a period of 24 hours dilates the uterine arteries of pregnant women with PE and/or IUGR, reduces uterine blood flow and improves the deformability of RBC. Both parameters enhance the oxygen supply to the fetus, a clinical parameter in these pregnancies. Thus magnesium might not only be effective as phrophylaxis against seizures but also in cases of IUGR with a reduced uterine blood flow. The clinically observed beneficial effect of magnesium in PE could be due to the improved blood supply for the fetus.
Burkhard Schauf; B Mannschreck; S Becker; K Dietz; D Wallwiener; B Aydeniz
Related Documents :
142933 - Uteroplacental blood flow and estrogen production following dehydroisoandrosterone infu...
11707663 - Major postpartum haemorrhage.
15933303 - Crisis management during anaesthesia: desaturation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hypertension in pregnancy     Volume:  23     ISSN:  1064-1955     ISO Abbreviation:  Hypertens Pregnancy     Publication Date:  2004  
Date Detail:
Created Date:  2004-12-24     Completed Date:  2005-02-01     Revised Date:  2014-07-23    
Medline Journal Info:
Nlm Unique ID:  9421297     Medline TA:  Hypertens Pregnancy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  331-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / pharmacology*
Calcium Channel Blockers / pharmacology
Erythrocyte Deformability / drug effects*,  physiology
Fetal Growth Retardation / physiopathology*
Magnesium Sulfate / pharmacology*
Microcirculation / drug effects,  physiology
Pre-Eclampsia / physiopathology*
Regional Blood Flow / drug effects
Ultrasonography, Doppler
Ultrasonography, Prenatal
Uterus / blood supply*,  ultrasonography
Vascular Resistance / drug effects
Reg. No./Substance:
0/Anticonvulsants; 0/Calcium Channel Blockers; 7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tumor necrosis factor-alpha in whole blood cultures of preeclamptic patients and healthy pregnant an...
Next Document:  An invasive strategy in non-ST-segment elevation acute coronary syndromes. From large trials to the ...